AstraZeneca PLC (AZN) - Quarterly EPS earnings growth

AstraZeneca PLC (AZN) is a leading biopharmaceutical behemoth providing treatments to patients and government agencies within the cardiology and oncology segments. The quarterly EPS growth trend captures this momentum, with 23.40 reflecting the latest level of the metric. The synergy of developments for rare pathologies creates a unique ecosystem, while the current portfolio of life-saving medicines guarantees sustainable demand and business growth.

astrazeneca.com (AZN) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

AZN (AstraZeneca Corp.): analytical breakdowns and indicator data

- share price and expert price forecast:

Stock Price AstraZeneca|AZN - Broker Consensus Forecast

- market capitalization indicators:

Market Capitalization AstraZeneca AB|AZN - Company Buyout Price

- balance sheet net asset value indicators:

Net Assets per Single Share AstraZeneca|AZN - Accounting Capitalization|Market Capitalization to Book Value Ratio astrazeneca.com|AZN - Company Balance Sheet Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

AZN - Net Profit|Future Profit AstraZeneca PLC|AZN - Market Cap to Net Income|Forward P/E Multiple AstraZeneca AB|AZN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AstraZeneca AB|AZN - Operating profit before amortization|Net earnings per share (EPS TTM) AstraZeneca|AZN - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth astrazeneca.com|AZN - Net earnings per share growth this year|Earnings growth forecast for next year AstraZeneca PLC

Analysis of all company metrics:AstraZeneca, AZN

This indicator measures the percentage deviation of net earnings per share for the current quarter relative to the same period last year. Positive momentum confirms growing fundamental impulse and efficient capital allocation. For AstraZeneca PLC (AZN), this growth is driven by patent monopolies and the successful navigation of regulatory barriers during drug launches. By analyzing the quarterly EPS growth rate, an investor can assess the business's resilience to market downturns.

Competitor analysis for AstraZeneca PLC

LLY: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ABBV|NVS (Novartis Inc.) - Quarterly EPS earnings growth|MSD (MRK) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Novo Nordisk A/S (NVO)|amgen.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PFE (Pfizer)|Net earnings per share growth for the trailing year Sanofi SA|BMS - Quarterly EPS earnings growth|GSK - Quarterly EPS earnings growth|Takeda Pharmaceutical (TAK) - Year-over-year earnings per share growth for the last twelve months|TEVA - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months RDY|VTRS (Viatris Inc) - Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Roivant Sciences Ltd (ROIV)|ZLAB (Zai Lab Corp) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BHC (Bausch Health Companies)|Quarterly EPS earnings growth cosmosholdingsinc.com COSM